Schedule 13G ownership disclosure
Obalon Therapeutics Inc
Security class unavailable · CUSIP: 67424L100
Event date: 2018-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 1,114,113
- Percent of class
- 4.6000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001628280-19-002886
- Form type
- SC 13G
- Filer
- ReShape Lifesciences Inc.
- CIK
- CIK 1427570
- Filed
- Mar 13, 2019
- Reporting period
- Dec 31, 2018
- Description
- Schedule 13G beneficial ownership